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Copyright © 2008 JCBN Summary The clinical efficacy of gastroprotective drugs or low-dose H2 receptor antagonists
in the prevention of nonsteroidal anti-inflammatory drug (NSAID)-induced gastropathy is
limited. The aim of the present study was to investigate efficacy of rebamipide and famotidine
in Helicobacter pylori (H. pylori)-negative healthy volunteers taking NSAID. This study was a
randomized, two way crossover study comparing the preventive effect rebamipide 100 mg, t.i.d.
and famotidine 10 mg, b.i.d against indomethacin (25 mg, t.i.d.)-induced gastric mucosal
injury in H. pylori-negative healthy volunteers. 12 subjects satisfied criteria and were random-
ized. Endoscopy was performed at baseline and again after the treatment for 7 days, and
symptoms were recorded during the treatment. Tissue levels of lipid peroxides and myeloper-
oxidase and serum indomethacin concentrations were also measured. Subjective symptoms
were developed in 58% (7/12) of the rebamipide group, and in 75% (9/12) of the famotidine
group (no significant differences). The incidence of gastric lesions (modified Lanza score 2 or
higher) was 17% (2/12) in the rebamipide group and 25% (3/12) in the famotidine group.
Peptic ulcers did not occur in both groups. There were no significant differences in tissue levels
of lipid peroxide and myeloperoxidase and serum level of indomethacin between two groups
after the treatment. In conclusion, these data recommend rebamipide (100 mg, t.i.d.) or famo-
tidine (10 mg, b.i.d.) for the prevention of acute gastric injury induced by NSAID in patients
without a particular risk factor.
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Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) such as
indomethacin are capable of producing injury to gastro-
intestinal mucosa in experimental animals and humans, and
their use is associated with a significant risk of hemorrhage,
erosions, and perforation of both gastric and intestinal ulcers
[1]. The molecular basis for the gastrointestinal toxicity of
NSAIDs is widely believed to their inhibitory activity against
cyclooxygenase, which causes them to block the production
of prostaglandins and their therapeutic actions. Suppression
of prostaglandin synthesis is associated with reduction of
gastric mucosal blood flow, disturbance of microcirculation,
decrease in mucus secretion, lipid peroxidation, and neutro-
phil activation, which are involved in the pathogenesis of
gastrointestinal mucosal disorders [1–4]. While the presence
of acid in the lumen of the stomach may not be a primaryPrevention of Indomethacin-induced Gastropathy
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factor in the pathogenesis of NSAID-induced gastropathy, it
can make an important contribution to the severity of these
lesions by impairing the restitution process, interfering with
hemostasis and inactivating several growth factors that are
important in mucosal defense and repair.
To make a strategy for the prevention of NSAID-induced
gastropathy, it is important to evaluate the risk factor of each
patient. Multiple factors have been identified that increase
risk for NSAID-related upper gastrointestinal complica-
tions. The highest risks are related to age (65 years) and prior
history of peptic ulcer; additional risk factors include use of
multiple NSAIDs, high doses of NSAIDs, and use of anti-
coagulants or steroid. Recent studies suggest that NSAID-
induced ulcers in at-risk patients can be prevented largely
through co-administration of a proton pump inhibitor to
block acid secretion in the stomach [5, 6].
The two most common causes of peptic ulcers are use of
NSAIDs and infection of Helicobacter pylori (H. pylori).
Although a synergy between H. pylori and NSAID use for
the development of peptic ulcers and ulcer bleeding has been
shown by a meta-analysis, the role played by H. pylori in
the development of overall gastrointestinal complications
remains a subject of controversy [7]. Interestingly, Kamada
et al. [8] have demonstrated that NSAID-associated gastric
ulcer frequently occur in the antrum with bleeding in
contrast to non-NSAID-associated gastric ulcers, and that
the rate of H. pylori infection in NSAID-associated gastric
ulcers is significantly lower than that in non-NSAID-
associated gastric ulcers. We have also reported that gastric
ulcer occurs in 30% of H. pylori-negative healthy volunteers
taking indomethacin (25 mg, t.i.d., 7 days), and that gastro-
protective drug rebamipide markedly inhibited these lesions
[9]. The aim of the present was to compare the efficacy
and tolerability of rebamipide and normal dose, not high
dose, famotidine in the prevention of NSAID-associated
gastrointestinal damage and related symptoms in H. pylori-
negative healthy volunteers.
Methods
Ethics
This study was conducted by gastroenterologists at the
Hikone Central Hospital. The ethics committee at the
Hikone Central Hospital approved the study protocol prior
to the start of the study, which was conducted in accordance
with Good Clinical Practice protocol. Prior to starting this
study, the investigators explained in detail to each subject
the aim and content of the study and the expected risks and
adverse reactions. Prior to participating in the trial, written
in formed consent was provided by each subject.
Protocol
This was a randomized, double blind, two-way crossover
study comparing the preventive effect of rebamipide and
famotidine against indomethacin-induced gastric mucosal
injury in healthy volunteers. All subjects were required to
undergo a complete medical history and physical examina-
tion, clinical laboratory tests including serum IgG antibody
against H. pylori, and a normal upper gastrointestinal endo-
scopy (i.e. grade 0 on the modified Lanza score) before the
first dose of each study medications. Subjects were excluded
from the study if they had an abnormal baseline endoscopy,
history of peptic ulcer disease or gastrointestinal bleeding, a
history of chronic disease, or a history of known alcohol
abuse or drug dependency. Subjects were also excluded if
clinical laboratory tests showed any abnormality or H.
pylori-positive, or if they received any anti-inflammatory
drug within 1 week of the study entry, or any drug within 1
month.
A total of 12 healthy male subjects between the ages of
Table 1. Clinical and gastric background of healthy volunteers
No. Age Sex Anti-Hp Ab
Chronic Inflammation
Atrophy
antrum body
1 20 male negative 0 0 0
2 21 male negative 0 0 0
3 20 male negative 0 0 0
4 22 male negative 0 0 0
5 23 male negative 1 0 0
6 22 male negative 0 0 0
7 23 male negative 0 0 0
8 24 male negative 0 0 0
9 22 male negative 0 0 0
10 24 male negative 0 0 0
11 21 male negative 1 1 0
12 21 male negative 0 0 0Y. Naito et al.
J. Clin. Biochem. Nutr.
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20–24 year who satisfied these inclusion and exclusion criteria
received first baseline endoscopic examination, and biopsy
specimens were taken from the greater curvature of gastric
body and the antrum 4 weeks prior to the therapeutic trial,
for the histological evaluation and the measurement of
myeloperoxidase (MPO) content and thiobarbituric acid
(TBA)-reactive substances. As shown in Table 1, all
subjects were male young healthy volunteers with non-
atrophic non-inflammatory normal gastric mucosa without
H. pylori infection. A second endoscopy was performed 4
weeks after the first to confirm disappearance of gastric
lesions produced by the first biopsy procedure. Subjects
were randomly assigned to one of two-treatment sequence in
a two-way crossover design. Each sequence involved
indomethacin 25 mg t.i.d. plus rebamipide (Mucosta®;
Otsuka Pharmaceutical Co., Inc., Tokyo, Japan) 100 mg t.i.d.
and indomethacin 25 mg t.i.d. plus famotidine (Gaster®;
Astellas Pharma Inc., Tokyo, Japan) 10 mg b.i.d.. On the
first day of treatment, a second endoscopy was performed in
the morning and two doses of study medication were then
taken over the remainder of the day. On the following 6
days, medication was taken three times daily. Finally, in the
morning on day 8, subjects received third endoscopic
examination, and biopsy specimens were taken from the
greater curvature or circumference of erosion of gastric body
and the antrum for the measurement of biochemical para-
meters. Consecutive study periods were separated by a
washout interval of 4 week. A 4th endoscopy was performed
4 weeks after the third to confirm disappearance of gastric
lesions.
Symptoms
Symptoms were recorded daily during the treatment
period; each subject noted the extent and severity of his
symptoms.
Gastric mucosal injury
The extent of gastric mucosal injury was assessed
according to the modified Lanza score (MLS, Table 1) [9,
10]. Endoscopy photographs with 20 or more image cuts
were sent to the endoscopic findings judge, who was outside
the Hikone central hospital. Endoscopists and the finding
judge were not informed of either the study drug or the date
of the photographs. To minimize the variance of endoscopy,
the same endoscopist used the same type of endoscope to
photograph the same region at the same angle for each
patient.
Histological study of gastric mucosa
Hematoxylin-eosin (H&E)-stained gastric mucosal speci-
mens were used to evaluate the extent of inflammation and
atrophy. The gastritis was graded using the visual analog
scale of the Updated Sydney System [11] as none (0), mild
(1), moderate (2), or marked (3). The following items were
evaluated separately: the acute inflammatory component of
gastritis (especially the amount of neutrophil infiltration),
chronic inflammatory gastritis (lymphoplasmacytic infiltra-
tion), gastric glandular atrophy on the basis of gland loss,
and intestinal metaplasia.
Measurement of lipid peroxides and myeloperoxidase
Gastric mucosal samples were suspended in phosphate-
buffered saline supplemented with 0.1% butylated hydroxy-
toluene and were frozen at –80°C until use. Later, tissue
homogenates were prepared, and the concentration of the
TBA-reactive substances was measured using the method of
Ohkawa et al. [12] as an index of lipid peroxidation. The
level of TBA-reactive substances in the mucosal homo-
genates was quantified using a 1,1,3,3-tetramethoxypropane
as the standard and expressed as nanomoles of malondialde-
hyde per mg protein. Total protein in the tissue homogenates
was measured using the Lowry method [13]. The tissue
homogenates were disrupted by ultrasonic sonication and
centrifuged at 12,000 g for 15 min. MPO concentrations in
the supernatant were measured by the enzyme immunoassay
(EIA) method using a kit (MPO kit, Bioxytech, Portland,
OR).
Measurement of H. pylori antibody
H. pylori antibody titers were measured by the HM-CAP
method using a kit manufactured by Kyowo Medex Co.,
Ltd., Tokyo, Japan).
Table 2. Gastric mucosal injury score (modified Lanza score, MLS)
Lanza score was partially modified by the criteria of Kobayashi and Mizushima [25].
Grade 0 No erosion/hemorrhage
Grade 1 Erosion and hemorrhage are localized in one area of the stomach; <2 lesions.
Grade 2 Erosion and hemorrhage are localized in one area of the stomach; 3–5 lesions.
Grade 3 Erosion and hemorrhage appear in two areas in the stomach. Although there are 
<10 erosions in the whole stomach, one area involves >6 erosions.
Grade 4 Erosion and hemorrhage appear over three or more areas in the stomach.
Grade 5 Gastric ulcerPrevention of Indomethacin-induced Gastropathy
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Measurement of indomethacin blood concentration
Blood sample were collected 12 h after the final adminis-
tration of trial medications, and serum concentration of
indomethacin was measured by the high-performance liquid
chromatography method.
Safety parameters
Adverse events occurring during the study were assessed
for their relationship to the study drug classified as “not
related”, “unlikely”, “likely”, or “definitely” related. The
following laboratory parameters were evaluated at baseline
and after treatment; hematology: erythrocytes, leukocytes,
thrombocytes, hematocrit, and hemoglobin; biochemical:
sodium, potassium, BUN, creatinine, total cholesterol,
triglycerides, glucose, total bilirubin, asparate amino-
transferase (AST), alanine aminotransferase (ALS), gamma-
glutamyl transpeptidase (γ-GT), and alkaline phosphatase
(ALP); urine analysis: protein, blood cells, and glucose.
Statistical analysis
The incidence of symptoms and gastric lesions of two
groups were compared by using Fisher’s exact probability
test. One-way analysis of variance (ANOVA) with Scheffe’s
multiple comparison test was performed when more than
two groups were compared. Differences in indomethacin
concentration were determined by Student’s t test. Differ-
ences were considered to be significant if the p value was
less than 0.05. All analyses were performed using the Stat
View 5.0-J program (Abacus Concepts, Inc., Berkeley, CA)
on a Macintosh computer.
Results
Symptoms
In the rebamipide group, 7 of 12 cases (58%) developed
subjective symptoms, while 9 of 12 cases (75%) in the
famotidine group developed (Table 3). However, no signifi-
cant difference was seen between the two groups (Fisher’s
exact probability test: p = 0.333). Epigastralgia, abdominal
fullness, and diarrhea are major symptoms in both groups.
The severity rating was mild to moderate for all complaints,
and there were no serious complications that resulted in
stopping medication in this study.
Gastric mucosal injury
The incidence of gastric lesions (MLS 2 or higher) was
17% (2/12) in the rebamipide group and 25% (3/12) in the
famotidine group (Fisher’s probability test: p = 0.500,
Table 4). Gastric ulcer did not occur in both groups.
Lipid peroxides and MPO concentrations in the gastric
mucosa
Gastric concentrations of TBA-reactive substances and
MPO tended to increase after the treatment (Table 5, 6).
However, there were no significant differences among three
groups by the ANOVA.
Blood indomethacin concentration
Serum indomethacin concentrations were 112.5 ± 21.4
ng/ml in the rebamipide group and 124.8 ± 28.4 ng/ml in
the famotidine group, showing no significant difference
between the groups.
Safety parameters
No abnormal test values were noted in the both groups.
Discussion
The present study described here is the first to compare
rebamipide, a gastroprotective drug, with low-dose famoti-
dine (20 mg/day) as prophylaxis against gastric injury and
symptoms induced by indomethacin in H. pylori-negative
healthy volunteers. We selected H. pylori-negative volunteers
by measuring anti-H. pylori IgG antibody and also
confirmed the normal gastric mucosa without inflammation
Table 3. Effects of rebamipide or famotidine on subjective
symptoms during therapeutic trials
Rebamipide group Famotidine group
(n = 12) (n =1 2 )
Symptoms (+) 7 (58%) 9 (75%)
Symptoms (−) 5 (42%) 3 (25%)
Epigastralgia 4 (33%) 4 (33%)
Heart burn 0 (0%) 2 (17%)
Nausea 1 (8%) 2 (17%)
Vomitting 0 (0%) 1 (8%)
Abdominal fullness 2 (17%) 2 (17%)
Poor appetite 0 (0%) 1 (8%)
Diarrhea 4 (33%) 4 (33%)
Gynecomastia 0 (0%) 1 (8%)
Table 4. Effects of rebamipide or famotidine on endoscopic
appearance of indomethacin-induced gastric mucosal
injury
Rebamipide group Famotidine group
(n = 12) (n =1 2 )
MLS 0/1 7/3 7/2
(83%) (75%)
MLS 2/3/4/5 0/2/0/0 1/2/0/0
(17%) (25%)
Gastric ulcer 0 0
(0%) (0%)Y. Naito et al.
J. Clin. Biochem. Nutr.
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or atrophy which was demonstrated by histological findings
of gastric corpus and antral biopsies. The reason why we
selected these subjects in the present study, is that it would
be able to assess pharmaceutical efficacy for acute gastric
mucosal injury induced by indomethacin precisely without
being affected by H. pylori infection or background mucosal
inflammation. The effect of H. pylori-infection on NSAIDs-
induced gastropathy is still controversial. Meta-analysis has
shown that H. pylori eradication reduces the incidence of
peptic ulcer in the overall population receiving NSAIDs
[14]. Nonetheless, H. pylori eradication seems less effective
than treatment with a maintenance proton pump inhibitor for
preventing NSAID-associated ulcers. In any event, the
purpose of the present study is not to assess the influence of
H. pylori infection on NSAID-gastropathy, but to compare
the protective effects of two drugs, rebamipide and famoti-
dine, against indomethacin-induced gastric mucosal injury
in volunteers with non-inflammatory and non-atrophic
gastric mucosa.
The primary end point of our study was to compare the
incidence of gastric mucosal injury (MLS 2 or higher) after
indomethacin administration. In our previous study which
was conducted by the completely same protocol; indo-
methacin treatment (25 mg, t.i.d., 7 days) for healthy volun-
teers, gastric lesions were found in seven (70%) of the 10
subjects (Fig. 1) [9]. Gastric ulcers occurred in 3 subjects
(30%). In contrast, the incidence of gastric lesions and ulcers
was 14% and 0%, respectively, in the rebamipide group. In
the present study, the incidence of gastric lesions was 17% in
the rebamipide group and 25% in the famotidine group,
respectively. There was no significant difference between
two groups. No gastric ulcers occurred in both groups. Since
there was no difference in the serum indomethacin
concentration between the groups, it is clear that the protec-
tive effects of these drugs on the gastric mucosa is not
mediated through changes in the absorption of indo-
methacin. Since rebamipide does not inhibit gastric acid or
pepsin secretion [15], it may prevent gastric injury by
affecting the gastric mucosal defense system. Although
many reports have demonstrated that rebamipide can reduce
indomethacin-induced gastric mucosal injury in murine
models [16–18], the present study reconfirmed its cyto-
protection in human. Clinical trials have also reported that
famotidine at high dosages provides preventive actions for
NSAIDs-associated gastric injury [19, 20]. This is a first
report showing that low-dose famotidine is effective for
preventing indomethacin-induced gastric injury in Japanese
healthy volunteers. These data suggest that rebamipide and
famotidine are equally effective for prevention of acute
gastric mucosal injury induced by indomethacin in H.
pylori-negative healthy volunteers without a particular risk
factor. Interestingly, a recent randomized, multicenter,
controlled trial showed that the rebamipide prevented
NSAID-induced peptic ulcer as effectively as misoprostol in
patients on long-term NSAID therapy [21]. These data
including the present data indicate that rebamipide may be a
useful candidate to prevent NSAID-induced gastric injury in
patients as well as healthy subjects.
To investigate the mechanism of cytoprotection by two
drugs, tissue levels of lipid peroxides and neutrophil in
the gastric mucosa were measured. The reason why we
measured these parameters in the present study is due to
accumulated evidence that lipid peroxidation mediated by
oxygen radicals derived from activated neutrophil play a
crucial role in the pathogenesis of NSAID-induced gastro-
Table 5. Effects of rebamipide or famotidine on the gastric
mucosal levels of lipid peroxides after the indomethacin
treatment
Each data indicate mean ± SE of 12 subjects.
(n = 12)
TBA-reactive substances 
(nmol/mg protein)
Antrum Body
Before treatment 0.98 ± 0.12 1.12 ± 0.34
Rebamipide group 1.11 ± 0.07 1.38 ± 0.16
Famotidine group 1.23 ± 0.14 1.47 ± 0.19
Table 6. Effects of rebamipide or famotidine on the gastric
mucosal neutrophil accumulation after the indomethacin
treatment
Each data indicate mean ± SE of 12 subjects.
(n = 12)
MPO content (ng/mg protein)
Antrum Body
Before treatment 2.73 ± 1.32 2.46 ± 0.80
Rebamipide group 9.24 ± 3.49 6.31 ± 2.67
Famotidine group 7.17 ± 3.31 4.14 ± 1.20
Fig. 1. Incidence of indomethacin-induced gastric lesion in
Helicobacter pylori-negative healthy volunteers.Prevention of Indomethacin-induced Gastropathy
Vol. 43, No. 1, 2008
39
pathy [2, 3, 22, 23]. The present data showed the inhibitory
tendency of these parameters by both drugs, however, there
was no statistical significance among groups. To confirm the
mechanism of these drugs, it will be needed to increase
sample number in a future study. Recent study have
demonstrated that the decrease in gastric mucosal blood
flow is associated with NSAID-induced gastric mucosal
injury, and rebamipide may have prevented NSIAD-induced
gastric mucosal injury by maintaining GMBF in healthy
subjects [24].
The secondary end point of our study was to compare the
incidence of subjective symptoms after indomethacin
administration. In terms of the incidence of subjective
symptoms, 58% of the subjects in the rebamipide group
developed symptoms including epigastralgia, abdominal
fullness, and diarrhea. Similary, 75% of the subjects in the
famotidine group developed similar symptoms. There was
no significant difference between two groups and there were
no serious complications that resulted in stopping medica-
tion during 7 days. Since previous studies have not demon-
strated a correlation between symptoms and endoscopic
findings in patients with NSAID-induced gastric mucosal
injury, it was important to assess the effects of these drugs on
the endoscopic findings. However, NSAID-induced these
dyspepsia may lead to discontinuation of treatment in 5%–
15% in the clinical field. Therefore, it may be also important
to reduce the dyspeptic symptoms induced by NSAID. In a
future study, it will be necessary to evaluate subjective
symptoms in addition to endoscopic findings especially in a
long-term use of NSAIDs.
In conclusion, we firstly demonstrated that rebamipide
and famotidine is equally effective in the prevention of
indomethacin-induced gastric injury in healthy volunteers.
These data recommend rebamipide (100 mg, t.i.d.) or famo-
tidine (10 mg, b.i.d.) for the prevention of acute gastric
injury induced by NSAID in patients without a particular
risk factor.
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